霍奇金淋巴瘤与女性生育力:多中心研究探讨接受多柔比星、博来霉素、长春花碱和达卡巴嗪治疗的女性
患者组治疗后至少1次妊娠比例53.7% vs 对照组54.5%(P=0.92),至妊娠中位时间患者组4.8年 vs 对照组6.8年,未见产科或新生儿并发症增加。
要点
- 接受ABVD治疗的霍奇金淋巴瘤女性妊娠率与健康对照无显著差异(53.7% vs 54.5%,P=0.92)。
- 有生育意愿的患者中81%至少实现1次妊娠。
- ABVD治疗后至妊娠中位时间患者组4.8年,对照组6.8年。
核心结论
- 接受ABVD方案治疗的霍奇金淋巴瘤年轻女性,其妊娠数、活产数及开始妊娠的时间与未暴露化疗的健康对照无差异。
研究设计与样本
- 非干预性多中心研究,纳入67例接受霍奇金淋巴瘤治疗的育龄期女性患者,每例患者匹配2名未暴露化疗的健康已产女性作为对照。
主要发现
- 患者组治疗后至少1次妊娠比例为53.7%,对照组为54.5%(P=0.92)。
- 有生育意愿的患者中81%至少实现1次妊娠。
- 至妊娠中位时间患者组为4.8年,对照组为6.8年。
- 患者组共58次妊娠和48次活产(比例1:2),对照组共136次妊娠和104次活产(比例1:3)。
- 本研究中未报告霍奇金淋巴瘤患者产科或新生儿并发症增加。
临床怎么用
- 作者认为,接受ABVD治疗的霍奇金淋巴瘤女性在生育力方面应得到 reassuring(原文为 should be reassured)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Preservation of fertility has become a growing concern in young females with Hodgkin lymphoma (HL). However, the rate of pregnancy after the current most frequently prescribed ABVD (doxorubicin [Adriamycin], bleomycin, vinblastine, and darcarbazine) chemotherapy for HL has rarely been studied. In this study, we aim to determine the impact of ABVD on the fertility of women treated for HL. We conducted a noninterventional, multicenter study of female patients of childbearing age who were treated for HL. Two healthy apparied women nonexposed to chemotherapy (our controls) were assigned for each patient. Fertility was assessed by the number of pregnancies and births after HL treatment. Sixty-seven patients were included. The median age at diagnosis was 24.4 years (range, 16-43). HL was a localized disease for 68.7%. Of all the patients, 53.7% started at least 1 pregnancy after treatment vs 54.5% of the controls (P = .92). Of all the patients who desired children, 81% had at least 1 pregnancy. Patients treated with ABVD did not have a longer median time to pregnancy (4.8 years in the group of patients and 6.8 years for controls). Across patients, there were 58 pregnancies and 48 births (ratio, 1:2) and 136 pregnancies and 104 births (ratio, 1:3) for the control cohort. No increase in obstetric or neonatal complications has been reported in HL in our study. The number of pregnancies, births, and the time to start a pregnancy in young women treated with ABVD for HL is not different from that of controls. Therefore, females with HL treated with ABVD should be reassured regarding fertility.
引用
- Machet A, Poudou C, Tomowiak C, et al. Hodgkin lymphoma and female fertility: a multicenter study in women treated with doxorubicin, bleomycin, vinblastine, and dacarbazine. Blood Adv. 2023. PMID: 36129842. doi:10.1182/bloodadvances.2021005557
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。